02.11.2010Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192

Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV).

Press Release

06.10.2010Pathwork Diagnostics Completes $30M Series C Round

Capital to Accelerate Commercialization and Market Share for FDA-cleared Tissue of Origin Test

Press Release

06.10.2010Amsterdam Molecular Therapeutics successfully raised €14.3m through an Equity Issue

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today that it has successfully raised € 14.3 m in gross proceeds through a private placement of new shares with institutional investors

Press Release